Yusi Anggriani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yusi Anggriani has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Elizabeth Pisani
Pancasila University
8 shared publications - Ayu Rahmawati
Pancasila University
5 shared publications - Amalia Hasnida
Health Care Governance, Erasmus University Rotterdam, Rotterdam, The Netherlands
4 shared publications - Mawaddati Rahmi
Affiliation Faculty of Pharmacy, Universitas Pancasila, Lenteng Agung, Jakarta Selatan, Indonesia
4 shared publications - William Nathanial Tjandrawidjaya
Pancasila University
4 shared publications - Hesty Utami Ramadaniati
Affiliation Faculty of Pharmacy, Universitas Pancasila, South Jakarta, Indonesia
3 shared publications
Latest Publications
- Open Access
Assessing the quality of amoxicillin in the private market in Indonesia: a cross-sectional survey exploring product variety, market volume and price factors
Objectives To assess the quality of amoxicillin products in Indonesia’s private market by surveying the range of products available across different areas, followed by product sampling and laboratory testing. Design A cross-sectional survey employing mystery shoppers to purposively sample the widest possible range of amoxicillin products available to patients across different areas in Indonesia. Setting Licensed and unlicensed medicine outlets in remote, rural and urban areas and online. Participants Amoxicillin products that are sold to patients as oral solid and dry liquid formulations. Main outcome measures Quality of amoxicillin products, assessed using compendial testing of active pharmaceutical ingredient content and dissolution. Samples that failed any quality test were classified as substandard or out-of-specification (OOS). The raw prevalence of substandard amoxicillin was adjusted based on the national market volume of each product variant. Results We surveyed 476 outlets, mostly pharmacies (68.5%), websites (19.7%) and drug stores (10.9%). Among the 120 collected samples, there were 59 distinct products, collectively representing 95% of the estimated market volume for oral solid products and 65% for dry syrups. 12 out of 110 oral solid samples tested OOS (10.9%), as did 3 out of 10 dry syrups (30%). The samples that failed originated from various areas and types of outlets. We found no relation between the price and quality of amoxicillin. Conclusions The oral solid amoxicillin products that tested OOS represent an estimated 12.7% of the national market volume. We found no relation between the price and quality of amoxicillin. Combining product-variety sampling with data on market volume presents a promising approach to gain insight into the prevalence of poor-quality medical products using a relatively small sample size.
Open AccessAssessing the quality of amoxicillin in the private market in Indonesia: a cross-sectional survey exploring product variety, market volume and price factors
Objectives To assess the quality of amoxicillin products in Indonesia’s private market by surveying the range of products available across different areas, followed by product sampling and laboratory testing. Design A cross-sectional survey employing mystery shoppers to purposively sample the widest possible range of amoxicillin products available to patients across different areas in Indonesia. Setting Licensed and unlicensed medicine outlets in remote, rural and urban areas and online. Participants Amoxicillin products that are sold to patients as oral solid and dry liquid formulations. Main outcome measures Quality of amoxicillin products, assessed using compendial testing of active pharmaceutical ingredient content and dissolution. Samples that failed any quality test were classified as substandard or out-of-specification (OOS). The raw prevalence of substandard amoxicillin was adjusted based on the national market volume of each product variant. Results We surveyed 476 outlets, mostly pharmacies (68.5%), websites (19.7%) and drug stores (10.9%). Among the 120 collected samples, there were 59 distinct products, collectively representing 95% of the estimated market volume for oral solid products and 65% for dry syrups. 12 out of 110 oral solid samples tested OOS (10.9%), as did 3 out of 10 dry syrups (30%). The samples that failed originated from various areas and types of outlets. We found no relation between the price and quality of amoxicillin. Conclusions The oral solid amoxicillin products that tested OOS represent an estimated 12.7% of the national market volume. We found no relation between the price and quality of amoxicillin. Combining product-variety sampling with data on market volume presents a promising approach to gain insight into the prevalence of poor-quality medical products using a relatively small sample size.
- Open Access
- 2 July 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2521434
On paper; in practice: measuring compliance with official pricing policies in a large field study of essential medicines in Indonesia
In 2015, Indonesia Ministry of Health (MoH) issued a decree to ensure the affordability of medicines by providing transparent prices which obliged all manufacturers to print a maximum retail price (MRP) on medicine primary packaging. We measure the compliance of manufacturers and retailers with the regulation stated in the decree and estimate the retailers’ profit. Five essential medicines (allopurinol, amlodipine, amoxicillin, cefixime, dexamethasone) were purchased from randomly selected health facilities, retail pharmacies and online outlets in Indonesia. We recorded retailer’s selling price and product’s MRP. We also sourced product’s list price and sales volume from pharmaceutical market data. We conducted an MRP policy implementation analysis by evaluating three indicators (retail price transparency, permitted MRP and permitted sales price). We also estimated the retailers’ profit by taking into account the profit margin and sales volume. Of 1249 sampled medicines, nearly all samples (99.4%) had visible MRP on their packaging indicating high transparency compliance. For unbranded generics, none complied with permitted MRP with a median ratio of printed MRP to permitted MRP being 3.5 (IQR 2.6–7.9), whilst higher compliance (11.2%) was observed for branded generics (IQR 1.1–1.7, median 1.1). 33% of the samples were sold above the printed MRP with the lowest compliance to actual selling price being documented in hospitals. Branded generics accounted for 79% of the product value across the study medicines and generated more profits than the unbranded versions. The transparency implementation through printed MRP and the compliance with permitted sales price regulation contribute to retailer accountability. Rules restricting permitted MRPs for unbranded generics, irrational since their inception, while they never set any limits at all on the price of branded medicines. This showed not enough evidence that the policy contributed to its objective of ensuring affordability.
- 2 July 2025
- Published by Taylor & Francis in Journal of Pharmaceutical Policy and Practice
- Vol. 18 (1) , 2521434
Open AccessOn paper; in practice: measuring compliance with official pricing policies in a large field study of essential medicines in Indonesia
In 2015, Indonesia Ministry of Health (MoH) issued a decree to ensure the affordability of medicines by providing transparent prices which obliged all manufacturers to print a maximum retail price (MRP) on medicine primary packaging. We measure the compliance of manufacturers and retailers with the regulation stated in the decree and estimate the retailers’ profit. Five essential medicines (allopurinol, amlodipine, amoxicillin, cefixime, dexamethasone) were purchased from randomly selected health facilities, retail pharmacies and online outlets in Indonesia. We recorded retailer’s selling price and product’s MRP. We also sourced product’s list price and sales volume from pharmaceutical market data. We conducted an MRP policy implementation analysis by evaluating three indicators (retail price transparency, permitted MRP and permitted sales price). We also estimated the retailers’ profit by taking into account the profit margin and sales volume. Of 1249 sampled medicines, nearly all samples (99.4%) had visible MRP on their packaging indicating high transparency compliance. For unbranded generics, none complied with permitted MRP with a median ratio of printed MRP to permitted MRP being 3.5 (IQR 2.6–7.9), whilst higher compliance (11.2%) was observed for branded generics (IQR 1.1–1.7, median 1.1). 33% of the samples were sold above the printed MRP with the lowest compliance to actual selling price being documented in hospitals. Branded generics accounted for 79% of the product value across the study medicines and generated more profits than the unbranded versions. The transparency implementation through printed MRP and the compliance with permitted sales price regulation contribute to retailer accountability. Rules restricting permitted MRPs for unbranded generics, irrational since their inception, while they never set any limits at all on the price of branded medicines. This showed not enough evidence that the policy contributed to its objective of ensuring affordability.
- Open Access
- 24 May 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (5) , e015416
Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia
Background: Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Industry groups warn unsustainably low prices threaten quality, while the government says medicines remain overpriced. We investigate the relationship between the price and quality of essential medicines and the affordability of medicines paid for out of pocket.Methods: We bought over 1000 samples of five common prescription medicines—allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone—online and from randomly selected pharmacies and health facilities in four regions across Indonesia. We recorded the price paid and tested samples for quality using high-performance liquid chromatography. We compared prices with the median and lowest prices for each medicine, tested for correlation between quality and price, and calculated affordability compared with the district minimum wage.Results: Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.3 to 18.6 times the median price for the medicine and dose (IQR: 0.9–5.0, median 1.4). Unbranded generics traded in a narrower range (range 0.1–2.6; IQR 0.6–1.0, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th percentile of available prices cost a maximum of 0.7% of 1 day’s wage for a course.Conclusion: In every study district, we found that Indonesian patients working at the minimum wage could access affordable, quality-assured versions of all studied essential medicines. More expensive brands were also widely available, but there was no relationship between price and quality.
- 24 May 2025
- Published by BMJ in BMJ Global Health
- Vol. 10 (5) , e015416
Open AccessAre quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia
Background: Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Industry groups warn unsustainably low prices threaten quality, while the government says medicines remain overpriced. We investigate the relationship between the price and quality of essential medicines and the affordability of medicines paid for out of pocket.Methods: We bought over 1000 samples of five common prescription medicines—allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone—online and from randomly selected pharmacies and health facilities in four regions across Indonesia. We recorded the price paid and tested samples for quality using high-performance liquid chromatography. We compared prices with the median and lowest prices for each medicine, tested for correlation between quality and price, and calculated affordability compared with the district minimum wage.Results: Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.3 to 18.6 times the median price for the medicine and dose (IQR: 0.9–5.0, median 1.4). Unbranded generics traded in a narrower range (range 0.1–2.6; IQR 0.6–1.0, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th percentile of available prices cost a maximum of 0.7% of 1 day’s wage for a course.Conclusion: In every study district, we found that Indonesian patients working at the minimum wage could access affordable, quality-assured versions of all studied essential medicines. More expensive brands were also widely available, but there was no relationship between price and quality.
- Open Access
- 23 September 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (9) , e015402
Value for money of medicine sampling and quality testing: evidence from Indonesia
Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines’ regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
- 23 September 2024
- Published by BMJ in BMJ Global Health
- Vol. 9 (9) , e015402
Open AccessValue for money of medicine sampling and quality testing: evidence from Indonesia
Background Substandard and falsified medicines (SFMs) are a public health concern of global importance. Postmarket surveillance in the form of medicine sampling and quality testing can prevent and detect SFM, however, there is remarkably scarce evidence about the cost and value for money of these activities: how much do they cost and how effective are they in detecting SFM? Methods Between February and October 2022, Systematic Tracking of At Risk Medicines (STARmeds) collected and analysed for quality 1274 samples of 5 medicines from physical and online retail outlets in 7 Indonesian districts. We collated data on the resources consumed by STARmeds, related to all stages of medicines sampling and quality testing including design, fieldwork and laboratory analysis. We used activity-based costing principles to calculate the financial and economic cost of medicine quality surveillance from the perspective of a hypothetical medicines’ regulator. We calculated the cost per day and per week of fieldwork, per sample collected and per substandard sample. We used bootstrapping to capture uncertainty in the number of samples collected, by seller location type (urban, rural and online). Results The total cost of sampling and testing medicines from the market was US$712 964 (current 2022 values). Laboratory costs represented the largest share (70%), followed by other direct costs (12%) and indirect costs (7%). On average, it costs STARmeds US$479 (95% CI US$462 to US$516) to collect one medicine sample and US$5990 (95% CI US$5601 to US$6258) to identify one substandard sample. Conclusion Our findings bring urgently needed and novel information on the cost and value for money of medicine quality surveillance. These may support planning and budgeting of the Indonesian pharmaceutical regulator, but also of regulators and researchers elsewhere, particularly in low-income and middle-income settings, as well as international organisations with health regulation and quality of care remits.
- Open Access
- 20 May 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Buying medicine online: Comparing the convenience, quality, and price of online vs. offline medicine (Preprint)
BACKGROUND People buy medicines online for various reasons, such as convenience and cost savings. In Indonesia, the Ministry of Health allows registered platforms to sell medicines online; however, unregistered sellers are still widely circulated. While numerous studies have highlighted the quality of online medicines, comparisons with medicines purchased from licensed physical pharmacies are rare. OBJECTIVE To explore the conveniences of buying medicine online on several online platforms in Indonesia, investigate the quality, and compare the price and quality of medicine bought online to medicine purchased in physical pharmacies. METHODS The online sellers were categorised by regulatory status, and the conveniences of each were explored. Between February and May 2022, samples were collected from 732 physical pharmacies and 328 online platforms. Quality and price comparisons were conducted across different types of medicine sellers. RESULTS Obtaining samples from other online sellers was not always easy. Some platforms have complex registration processes, and we found locating unregulated sellers challenging. Notably, 58.8% of sampled medicines exceeded the median retail price from physical pharmacies for the same dose and form. Branded generic medicines exhibited the widest price variation, ranging from 0.15 to 16.4 times the median offline retail price, while generic medicines ranged from 0.18 to 4.1 times. Regarding quality, the failure rates were 7.9% online and 8.7% offline, showing no significant difference. Among online sellers, unregulated ones had a higher failure rate (11.2%) compared to regulated (3.0%) and semi-regulated (4.5%) sellers. Antibiotics were 2.6 times more likely to fail quality tests than other medicines (13.8% vs. 5.1%). CONCLUSIONS The conveniences of purchasing medicine online vary among sellers, and prices are not consistently lower than offline sellers. In terms of quality, as long as patients buy medicine online from regulated sellers, they don’t have to worry about the quality of medicines.
- 20 May 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessBuying medicine online: Comparing the convenience, quality, and price of online vs. offline medicine (Preprint)
BACKGROUND People buy medicines online for various reasons, such as convenience and cost savings. In Indonesia, the Ministry of Health allows registered platforms to sell medicines online; however, unregistered sellers are still widely circulated. While numerous studies have highlighted the quality of online medicines, comparisons with medicines purchased from licensed physical pharmacies are rare. OBJECTIVE To explore the conveniences of buying medicine online on several online platforms in Indonesia, investigate the quality, and compare the price and quality of medicine bought online to medicine purchased in physical pharmacies. METHODS The online sellers were categorised by regulatory status, and the conveniences of each were explored. Between February and May 2022, samples were collected from 732 physical pharmacies and 328 online platforms. Quality and price comparisons were conducted across different types of medicine sellers. RESULTS Obtaining samples from other online sellers was not always easy. Some platforms have complex registration processes, and we found locating unregulated sellers challenging. Notably, 58.8% of sampled medicines exceeded the median retail price from physical pharmacies for the same dose and form. Branded generic medicines exhibited the widest price variation, ranging from 0.15 to 16.4 times the median offline retail price, while generic medicines ranged from 0.18 to 4.1 times. Regarding quality, the failure rates were 7.9% online and 8.7% offline, showing no significant difference. Among online sellers, unregulated ones had a higher failure rate (11.2%) compared to regulated (3.0%) and semi-regulated (4.5%) sellers. Antibiotics were 2.6 times more likely to fail quality tests than other medicines (13.8% vs. 5.1%). CONCLUSIONS The conveniences of purchasing medicine online vary among sellers, and prices are not consistently lower than offline sellers. In terms of quality, as long as patients buy medicine online from regulated sellers, they don’t have to worry about the quality of medicines.
- Open Access
Are quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia
Background Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Public narratives have questioned the quality of low-cost medicines, including those provided free to insured patients. We investigate the relationship between medicine price and quality, and the affordability of medicines paid for out of pocket. Methods We bought over 1,000 samples of five common prescription medicines -- allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone -- online and from randomly-selected pharmacies and health facilities in four regions across Indonesia, recording price paid, and testing samples for quality using high performance liquid chromatography. We compared prices with the median price for the same medicine; tested for correlation between quality and price, and calculated affordability compared with the district minimum wage. Results Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.1 to 23.1 times the median price for the medicine and dose (interquartile range: 0.9 – 4.8, median 1.4). Unbranded generics traded in a narrower range (range: 0.1 – 3.2; IQR: 0.5 - 1, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th centile of available prices cost a maximum of 0.7% of one day’s wage for a course. Conclusion Though medicine price vary very widely in Indonesia, we found that affordable varieties of common prescription medicines were widely available across the country, and these medicines were no more likely to fail quality testing than those costing several times as much.
Open AccessAre quality medicines affordable? Evidence from a large survey of medicine price and quality in Indonesia
Background Since Indonesia implemented one of the world’s largest single-payer health insurance schemes in 2014, the price of many common medicines has fallen dramatically. Public narratives have questioned the quality of low-cost medicines, including those provided free to insured patients. We investigate the relationship between medicine price and quality, and the affordability of medicines paid for out of pocket. Methods We bought over 1,000 samples of five common prescription medicines -- allopurinol, amlodipine, amoxicillin, cefixime and dexamethasone -- online and from randomly-selected pharmacies and health facilities in four regions across Indonesia, recording price paid, and testing samples for quality using high performance liquid chromatography. We compared prices with the median price for the same medicine; tested for correlation between quality and price, and calculated affordability compared with the district minimum wage. Results Medicines available in the public procurement system were less likely to fail quality testing than other brands/varieties (4.2% vs 8.3%) but the difference was not statistically significant (p=0.086). There was no other relationship between quality and price, or branded status. Branded generic medicines sold at a large variety of price points, from 0.1 to 23.1 times the median price for the medicine and dose (interquartile range: 0.9 – 4.8, median 1.4). Unbranded generics traded in a narrower range (range: 0.1 – 3.2; IQR: 0.5 - 1, median 0.8). Medicines were most expensive in the region with the lowest wages, but even there, medicines selling at the 25th centile of available prices cost a maximum of 0.7% of one day’s wage for a course. Conclusion Though medicine price vary very widely in Indonesia, we found that affordable varieties of common prescription medicines were widely available across the country, and these medicines were no more likely to fail quality testing than those costing several times as much.
- Open Access
- 22 December 2023
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (1) , 1-10
Quality and potency of government-subsidized antibiotics in hospitals Jakarta, Indonesia
Several pharmaceutical companies have long complained that the price of medicines that win the e-catalogue tender is too low, in some cases even below the cost of production. However, it should not be a concern that only pharmaceutical products with regulation of Indonesian food and drug (BPOM) distribution licenses are eligible for the price tender, as they are of good quality. This study aims to determine the quality and potency of three antibiotic drugs based on their highest utilization (DU 90%) in pneumonia patients at two hospitals, A (ceftriaxone, azithromycin tablet) and B (ceftriaxone, levofloxacin infusion) compared to brand name. The quality of the samples was evaluated following the Indonesian Pharmacopoeia 6th Edition (FI-VI). Antibiotic potency was assessed using the Plate-Cylinder Method with K. pneumonia from human and S. pneumonia ATCC 10015 as the test bacteria evaluated following CLSI. All samples meet the criteria of FI-VI antibiotic content, weight uniformity, dissolution. Antibiotic potency all samples test S.pneumonia and K.pneumonia were sensitive but ceftriaxone test with K.pneumonia was resistance. All antibiotic tablets and injections studied met the requirements of the Indonesian Pharmacopoeia Edition 6 for active medicinal ingredient content, dosage weight uniformity, and dissolution. All drugs from hospitals (INN) have lower antibiotic potency than branded drugs. This highlight the importance of conducting microbiological testing on antibiotic preparations.
- 22 December 2023
- Published by Etflin in Sciences of Pharmacy
- Vol. 3 (1) , 1-10
Open AccessQuality and potency of government-subsidized antibiotics in hospitals Jakarta, Indonesia
Several pharmaceutical companies have long complained that the price of medicines that win the e-catalogue tender is too low, in some cases even below the cost of production. However, it should not be a concern that only pharmaceutical products with regulation of Indonesian food and drug (BPOM) distribution licenses are eligible for the price tender, as they are of good quality. This study aims to determine the quality and potency of three antibiotic drugs based on their highest utilization (DU 90%) in pneumonia patients at two hospitals, A (ceftriaxone, azithromycin tablet) and B (ceftriaxone, levofloxacin infusion) compared to brand name. The quality of the samples was evaluated following the Indonesian Pharmacopoeia 6th Edition (FI-VI). Antibiotic potency was assessed using the Plate-Cylinder Method with K. pneumonia from human and S. pneumonia ATCC 10015 as the test bacteria evaluated following CLSI. All samples meet the criteria of FI-VI antibiotic content, weight uniformity, dissolution. Antibiotic potency all samples test S.pneumonia and K.pneumonia were sensitive but ceftriaxone test with K.pneumonia was resistance. All antibiotic tablets and injections studied met the requirements of the Indonesian Pharmacopoeia Edition 6 for active medicinal ingredient content, dosage weight uniformity, and dissolution. All drugs from hospitals (INN) have lower antibiotic potency than branded drugs. This highlight the importance of conducting microbiological testing on antibiotic preparations.
- Open Access
- 3 November 2023
- Published by Universitas Muhammadiyah Ahmad Dahlan Cirebon in Medical Sains : Jurnal Ilmiah Kefarmasian
- Vol. 8 (4)
COST-EFFECTIVENESS ANALYSIS OF ANTICOAGULANT USAGE IN COVID-19 PATIENTS AT 45 KUNINGAN HOSPITAL
Cost-effectiveness analysis (CEA) is a pharmacoeconomic method that compares prices from all sources consumed (cost) with the outcome value of a program or intervention to obtain objective answers to the selection of drugs that are effective in terms of benefits and costs. COVID-19, or Coronavirus Disease 2019, is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) and causes acute respiratory distress, including fever, coughing, and shortness of breath. Fondaparinux, aside from heparin and enoxaparin, can be given as an anticoagulant therapeutic option in hospitalized COVID-19 patients, according to the third edition of the COVID-19 care recommendations. This study aimed to find the most cost-effective therapy among heparin, enoxaparin, and fondaparinux in COVID-19 patients at the RSUD’45 Kuningan. It also applied descriptive non-experimental research methods with retrospectively collected data. The intervention that had been studied was the administration of anticoagulant medication, where the effectiveness of the drug was observed in the reduction of D-dimer levels to normal levels. Meanwhile, the costs were observed from the perspective of a healthcare provider, specifically the RSUD’45 Kuningan. The study sample included 107 patients, with 13 receiving heparin, 41 receiving enoxaparin, and 53 receiving fondaparinux. Bivariate analysis using the chi-square test revealed no significant difference between the drug groups in the proportion of patients who improved and did not improve (sig. value = 0.610)...
- 3 November 2023
- Published by Universitas Muhammadiyah Ahmad Dahlan Cirebon in Medical Sains : Jurnal Ilmiah Kefarmasian
- Vol. 8 (4)
Open AccessCOST-EFFECTIVENESS ANALYSIS OF ANTICOAGULANT USAGE IN COVID-19 PATIENTS AT 45 KUNINGAN HOSPITAL
Cost-effectiveness analysis (CEA) is a pharmacoeconomic method that compares prices from all sources consumed (cost) with the outcome value of a program or intervention to obtain objective answers to the selection of drugs that are effective in terms of benefits and costs. COVID-19, or Coronavirus Disease 2019, is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARSCoV-2) and causes acute respiratory distress, including fever, coughing, and shortness of breath. Fondaparinux, aside from heparin and enoxaparin, can be given as an anticoagulant therapeutic option in hospitalized COVID-19 patients, according to the third edition of the COVID-19 care recommendations. This study aimed to find the most cost-effective therapy among heparin, enoxaparin, and fondaparinux in COVID-19 patients at the RSUD’45 Kuningan. It also applied descriptive non-experimental research methods with retrospectively collected data. The intervention that had been studied was the administration of anticoagulant medication, where the effectiveness of the drug was observed in the reduction of D-dimer levels to normal levels. Meanwhile, the costs were observed from the perspective of a healthcare provider, specifically the RSUD’45 Kuningan. The study sample included 107 patients, with 13 receiving heparin, 41 receiving enoxaparin, and 53 receiving fondaparinux. Bivariate analysis using the chi-square test revealed no significant difference between the drug groups in the proportion of patients who improved and did not improve (sig. value = 0.610)...
- Open Access
A randomised survey of the quality of antibiotics and other essential medicines in Indonesia, with volume-adjusted estimates of the prevalence of substandard medicines
Introduction Most substandard and falsified medicines are at best not optimally effective, and at worst fatal. While the World Health Organisation and others warn they are a major threat to public health in low and middle income countries, little is known about their true prevalence. Authors of meta-analyses universally warn that survey data are not generalisable, because of unrepresentative study designs and variations in medicines included; tests performed; reference standards and pharmacopeia used; and definitions used when translating multiple quality parameters into a single pass/fail measure. We hypothesised that weighting for sales volume of different products and brands would increase accuracy of estimates of medicine quality. Methods and Findings We collected samples of allopurinol, amlodipine, cefixime and dexamethasone, as well as amoxicillin in 2 formulations in seven districts across Indonesia, the world’s fourth most populous country. Outlets, including retail pharmacies, over the counter medicine shops, public and private hospitals, primary health centres, doctors and nurses were randomised. We also sampled from the internet. Retail samples were collected by mystery shoppers, other samples overtly. We tested 1274 samples for identity and assay, and all relevant samples for dissolution and uniformity of content, using USP reference standards and monographs. Samples that failed any laboratory test were considered out of specification. We calculated prevalence per product and brand, and weighted the results by the sales volume of each product, using sales data from IQVIA and the national public procurement system. The weighted prevalence of out-of-specification products was 4.9%, 40.3% lower than the raw estimate (8.2%). Antibiotics were more likely to be substandard (weighted prevalence 6.8 vs 3.1; raw prevalence 13.6 vs 4.9, pConclusions Where data are available, weighting survey results by sales volume is a cost-effective way of improving the accuracy of estimates of out-of-specification medicines measured in field surveys.
Open AccessA randomised survey of the quality of antibiotics and other essential medicines in Indonesia, with volume-adjusted estimates of the prevalence of substandard medicines
Introduction Most substandard and falsified medicines are at best not optimally effective, and at worst fatal. While the World Health Organisation and others warn they are a major threat to public health in low and middle income countries, little is known about their true prevalence. Authors of meta-analyses universally warn that survey data are not generalisable, because of unrepresentative study designs and variations in medicines included; tests performed; reference standards and pharmacopeia used; and definitions used when translating multiple quality parameters into a single pass/fail measure. We hypothesised that weighting for sales volume of different products and brands would increase accuracy of estimates of medicine quality. Methods and Findings We collected samples of allopurinol, amlodipine, cefixime and dexamethasone, as well as amoxicillin in 2 formulations in seven districts across Indonesia, the world’s fourth most populous country. Outlets, including retail pharmacies, over the counter medicine shops, public and private hospitals, primary health centres, doctors and nurses were randomised. We also sampled from the internet. Retail samples were collected by mystery shoppers, other samples overtly. We tested 1274 samples for identity and assay, and all relevant samples for dissolution and uniformity of content, using USP reference standards and monographs. Samples that failed any laboratory test were considered out of specification. We calculated prevalence per product and brand, and weighted the results by the sales volume of each product, using sales data from IQVIA and the national public procurement system. The weighted prevalence of out-of-specification products was 4.9%, 40.3% lower than the raw estimate (8.2%). Antibiotics were more likely to be substandard (weighted prevalence 6.8 vs 3.1; raw prevalence 13.6 vs 4.9, pConclusions Where data are available, weighting survey results by sales volume is a cost-effective way of improving the accuracy of estimates of out-of-specification medicines measured in field surveys.
- Open Access
- 16 August 2021
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 7 (8) , e29309
Substandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance
The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying “cases” for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.
- 16 August 2021
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 7 (8) , e29309
Open AccessSubstandard and Falsified Medicines: Proposed Methods for Case Finding and Sentinel Surveillance
The World Health Organization and others warn that substandard and falsified medicines harm health and waste money, especially in low- and middle-income countries. However, no country has measured the market-wide extent of the problem, and no standardized methods exist to estimate the prevalence of either substandard or falsified medicines. This is, in part, because the task seems overwhelming; medicine markets are huge and diverse, and testing medicines is expensive. Many countries do operate some form of postmarket surveillance of medicine, but their methods and goals differ. There is currently no clear guidance on which surveillance method is most appropriate to meet specific public health goals. In this viewpoint, we aimed to discuss the utility of both case finding and risk-based sentinel surveillance for substandard and falsified medicines, linking each to specific public health goals. We posit that choosing the system most appropriate to the goal, as well as implementing it with a clear understanding of the factors driving the production and sale of substandard and falsified medicines, will allow for surveillance resources to be concentrated most efficiently. We adapted principles used for disease outbreak responses to suggest a case-finding system that uses secondary data to flag poor-quality medicines, proposing risk-based indicators that differ for substandard and falsified medicines. This system potentially offers a cost-effective way of identifying “cases” for market withdrawal, enhanced oversight, or another immediate response. We further proposed a risk-based sentinel surveillance system that concentrates resources on measuring the prevalence of substandard and falsified medicines in the risk clusters where they are most likely to be found. The sentinel surveillance system provides base data for a transparent, spreadsheet-based model for estimating the national prevalence of substandard and falsified medicines. The methods we proposed are based on ongoing work in Indonesia, a large and diverse middle-income country currently aiming to achieve universal health coverage. Both the case finding and the sentinel surveillance system are designed to be adaptable to other resource-constrained settings.